New hope for tough lymphoma: drug cocktail shows promise

NCT ID NCT05267054

Completed Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tested a new drug called ociperlimab combined with either tislelizumab or rituximab in 53 people whose diffuse large B-cell lymphoma had returned or stopped responding to treatment. The main goal was to check safety and find the right dose. Researchers also looked at whether the tumors shrank. The study is complete, but results are not yet published.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ociperlimab, Tislelizumab, Rituximab
What this could lead to: If successful, this combination could offer a new treatment option for people with hard-to-treat diffuse large B-cell lymphoma.
What could go wrong: This is an early-phase trial with only 53 participants, so results may not apply broadly. Side effects from the drug combination could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma lymphoma neoplasm relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA RELAPSED DIFFUSE LARGE B CELL LYMPHOMA

Contacts and locations

Locations

Affiliated Zhongshan Hospital of Fudan University

Shanghai, Shanghai Municipality, 200032, China
Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, 100050, China
Beijing Hospital

Beijing, Beijing Municipality, 100730, China
Guangdong Provincial Peoples Hospital

Guangzhou, Guangdong, 510080, China
Henan Cancer Hospital

Zhengzhou, Henan, 450000, China
Hunan Cancer Hospital

Changsha, Hunan, 410013, China
Jiangxi Province Cancer Hospital

Nanchang, Jiangxi, 330029, China
Shandong Cancer Hospital

Jinan, Shandong, 250117, China
Shengjing Hospital of China Medical University

Shenyang, Liaoning, 110004, China
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital

Chengdu, Sichuan, 610071, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310016, China
Sun Yat Sen University Cancer Center

Guangzhou, Guangdong, 510060, China
The First Affiliated Hospital of Nanchang University Branch Donghu

Nanchang, Jiangxi, 330006, China
Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, 300060, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China
West China Hospital, Sichuan University

Chengdu, Sichuan, 610041, China
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, 310022, China
Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.